Background/Aim: Pseudomyogenic hemangioendothelioma is a rare endothelial tumor. Previous genetic investigations have shown that the tumors carry either a SERPINE1-FOSB or an ACTB-FOSB fusion gene. The aim of the study was to identify FOSB fusions linked with pseudomyogenic hemangioendothelioma. Materials and Methods: RNA sequencing, reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing analyses were performed on a pseudomyogenic hemangioendothelioma. Results: An in-frame fusion was found between exon 4 of WWTR1 from 3q25 and exon 2 of FOSB from 19q13. The fusion gene not only places FOSB under the control of the WWTR1 promoter, but is predicted to encode a chimeric WWTR1-FOSB transcription factor. Conclusion: FOSB may be fused with SERPINE1, ACTB, or WWTR1 in pseudomyogenic hemangioendotheliomas. The resulting overexpression of FOSB fusion is a potentially useful marker that could be helpful in the diagnosis of these tumors.
CITATION STYLE
Panagopoulos, I., Lobmaier, I., Gorunova, L., & Heim, S. (2019). Fusion of the genes WWTR1 and FosB in pseudomyogenic hemangioendothelioma. Cancer Genomics and Proteomics, 16(4), 293–298. https://doi.org/10.21873/cgp.20134
Mendeley helps you to discover research relevant for your work.